Skip to main content
Midas Edge

Passage BIO Inc

For the period ended Sep 30, 2024. Filed Nov 13, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 13, 2024

PASG$3.43-13.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Statements of Stockholders’ Equity

​​​​​​​​​​​​​​​​​
​ · ​ · Common stock · ​ · Additional · ​ · ​ · Accumulated other · ​ · ​ · Accumulated · ​ · ​ · ​
(in thousands, except share data) · Shares · Amount · paid‑in capital · ​ · ​ · comprehensive income (loss) · ​ · deficit · ​ · Total
Balance at July 1, 202461,754,786​$6$717,788​$(67)​$(627,170)​$90,557
Exercise of stock options and vesting of restricted stock units12,500​——​—​—​—
Unrealized gain (loss) on marketable securities—​——​99​—​99
Share‑based compensation expense—​—1,400​—​—​1,400
Net loss—​——​—​(19,340)​(19,340)
Balance at September 30, 202461,767,286​$6$719,188​$32​$(646,510)​$72,716
​​​​​​​​​​​​​​​​​
​​​​​​​​​​​​​​​​​
​​Common stock​Additional​​Accumulated other​​Accumulated​​​
(in thousands, except share data)SharesAmountpaid‑in capital​​comprehensive income (loss)​deficit​Total
Balance at January 1, 202454,944,130​$5$705,789​$(43)​$(594,468)​$111,283
Issuance of common stock under the ATM Facility, net of offering costs​6,000,000​​1​8,741​​—​​—​​8,742
Exercise of stock options and vesting of restricted stock units724,591​—35​—​—​35
Issuance of shares in connection with employee stock purchase plan​98,565​​—​50​​—​​—​​50
Unrealized gain (loss) on marketable securities—​——​75​—​75
Share‑based compensation expense—​—4,573​—​—​4,573
Net loss—​——​—​(52,042)​(52,042)
Balance at September 30, 202461,767,286​$6$719,188​$32​$(646,510)​$72,716

Statements of Stockholders’ Equity

​​​​​​​​​​​​​​​​​
​ · ​ · Common stock · ​ · Additional · ​ · ​ · Accumulated other · ​ · ​ · Accumulated · ​ · ​ · ​
(in thousands, except share data) · ​ · Shares · ​ · Amount · ​ · paid‑in capital · ​ · ​ · comprehensive income (loss) · ​ · deficit · ​ · Total
Balance at July 1, 202354,745,680​$5$701,349​$(340)​$(550,600)​$150,414
Exercise of stock options and vesting of restricted stock units67,292​​—​—​​—​​—​​—
Unrealized gain (loss) on marketable securities—​​——​​148​​—​​148
Share‑based compensation expense—​​—​2,824​​—​​—​​2,824
Net loss—​​—​—​​—​​(27,110)​​(27,110)
Balance at September 30, 2023​54,812,972​$5$704,173​$(192)​$(577,710)​$126,276
​​​​​​​​​​​​​​​​​
​​​​​​​​​​​​​​​​​
​​​​​​​​​​​​​​​​​
​​Common stock​Additional​​Accumulated other​​Accumulated​​​
(in thousands, except share data)Shares​Amount​paid‑in capital​​comprehensive income (loss)​deficit​Total
Balance at January 1, 202354,614,690​$5$694,733​$(966)​$(492,406)​$201,366
Exercise of stock options and vesting of restricted stock units​98,042​​—​—​​—​​—​​—
Issuance of shares in connection with employee stock purchase plan​100,240​​—​89​​—​​—​​89
Unrealized gain (loss) on marketable securities​—​​——​​774​​—​​774
Share‑based compensation expense—​​—​9,351​​—​​—​​9,351
Net loss—​​—​—​​—​​(85,304)​​(85,304)
Balance at September 30, 202354,812,972​$5$704,173​$(192)​$(577,710)​$126,276
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.